Form : Tablets
/ Pack : 10 X 10’s
/ Type : Alu Alu
Description : Telmisartan is an angiotensin II receptor blocker that shows high affinity for the angiotensin II receptor type 1 (AT1), with a binding affinity 3000 times greater for AT1 than AT2.
In addition to blocking the renin–angiotensin system, telmisartan acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. It is believed that telmisartan's dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease (CVD).
Description : Telmisartan is an angiotensin II receptor blocker that shows high affinity for the angiotensin II receptor type 1 (AT1), with a binding affinity 3000 times greater for AT1 than AT2.
In addition to blocking the renin–angiotensin system, telmisartan acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. It is believed that telmisartan's dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease (CVD). Telmisartan's activity at the peroxisome proliferator-activated receptor delta (PPAR-δ) receptor has prompted speculation around its potential as a sport doping agent as an alternative to GW 501516. Telmisartan activates PPAR-δ receptors in several tissues.
Description : Since Cilnidipine inhibits N-type channels thus it inhibits the activation of the sympathetic nervous system hence preferred drug for White Coat Hypertension and morning hypertension (closely associated with sympathetic activity) Cilnidipine has been extensively studied by researchers in its preclinical and clinical development phases. Renoprotective, neuroprotective and cardioprotective effects of Cilnidipine have been demonstrated in clinical practice - Indian Heart J. 2013 Dec; 65(6): 691–695.Bisoprolol is a beta-blocker with high selectivity for beta-1 ARs. It has no intrinsic sympathomimetic activity and no membrane stabilizing activity. Lacking of any ancillary property, it may probably be considered as “the purest” beta-1 AR blocker for the treatment of HF- Ther Clin Risk Manag. 2007 Aug; 3(4): 569–578.
Description : The study indicates that unlike Amlodipine, Cilnidipine which inhibits L-and N-type calcium channels will be useful for patients with hypertension and cardiovascular disease, diabetes mellitus or renal disease and proves to be a better alternative to existing calcium channel blockers.- Int J Basic Clin Pharmacol. 2013; 2(2): 160-164.
Description : The study indicates that unlike Amlodipine, Cilnidipine which inhibits L-and N-type calcium channels will be useful for patients with hypertension and cardiovascular disease, diabetes mellitus or renal disease and proves to be a better alternative to existing calcium channel blockers.- Int J Basic Clin Pharmacol. 2013; 2(2): 160-164.
Description : Preliminary evidence suggests that the blood pressure-lowering effects of candesartan are associated with the prevention or improvement of end-organ damage in patients with hypertension. Candesartan improves insulin sensitivity in patients with hypertension and does not affect glucose homeostasis or the serum lipid profile in those with coexisting type 2 (non-insulin-dependent) diabetes mellitus. Candesartan is well tolerated in patients with hypertension. Pooled data indicate that the tolerability profile of the drug is not significantly different from that of placebo, with headache being the most commonly reported event. Candesartan is better tolerated than enalapril, primarily because of a reduced incidence of cough and was not associated with the hypokalaemia or hyperuricaemia seen with hydrochlorothiazide in a study in patients aged > or = 75 years - Drugs. 1998 Nov;56(5):847-69.
Description : Preliminary evidence suggests that the blood pressure-lowering effects of candesartan are associated with the prevention or improvement of end-organ damage in patients with hypertension. Candesartan improves insulin sensitivity in patients with hypertension and does not affect glucose homeostasis or the serum lipid profile in those with coexisting type 2 (non-insulin-dependent) diabetes mellitus. Candesartan is well tolerated in patients with hypertension. Pooled data indicate that the tolerability profile of the drug is not significantly different from that of placebo, with headache being the most commonly reported event. Candesartan is better tolerated than enalapril, primarily because of a reduced incidence of cough and was not associated with the hypokalaemia or hyperuricaemia seen with hydrochlorothiazide in a study in patients aged > or = 75 years - Drugs. 1998 Nov;56(5):847-69.
Form : Tablets
/ Pack : 10 x 10's
/ Type : ALU-ALU
Description : Benazepril is a class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies and to prevent stroke, myocardial infarction and cardiac death in high-risk patients. Benazepril competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin-I to angiotensin-II. This prevents the potent vasoconstrictive actions of angiotensin-II resulting in vasodilation. Benazepril also decreases angiotensin-II induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.
Form : Tablets
/ Pack : 10 x 10's
/ Type : ALU-ALU
Description : The angiotensin-II–receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes- New England J Med 2001; 345:851-860. There is some evidence that irbesartan provides protective cardiovascular effects beyond its antihypertensive action. This is particularly true for its beneficial effects on slowing the progression of early-stage and late-stage renal disease in hypertensive patients with type 2 diabetes and on promoting regression of left ventricular mass in patients with hypertension and left ventricular hypertrophy. Recent research has further highlighted the positive role of irbesartan in preventing recurrence of arrhythmia in patients with persistent atrial fibrillation, when added to classical antiarrhythmic therapy. Finally, some data suggest an additional benefit in cardiac disease, through a reduction in the risk of heart failure episodes, as observed with other angiotensin receptor blockers- Integr Blood Press Control. 2011; 4: 17–26.
Form : Tablets
/ Pack : 10 x 10's
/ Type : ALU-ALU
Description : The angiotensin-II–receptor blocker irbesartan is effective in protecting against
the progression of nephropathy due to type 2 diabetes. This protection is independent of the
reduction in blood pressure it causes- New England J Med 2001; 345:851-860. There is some
evidence that irbesartan provides protective cardiovascular effects beyond its antihypertensive
action. This is particularly true for its beneficial effects on slowing the progression of early-stage
and late-stage renal disease in hypertensive patients with type 2 diabetes and on promoting
regression of left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Recent research has further highlighted the positive role of irbesartan in preventing recurrence
of arrhythmia in patients with persistent atrial fibrillation, when added to classical antiarrhythmic
therapy. Finally, some data suggest an additional benefit in cardiac disease, through a reduction
in the risk of heart failure episodes, as observed with other angiotensin receptor blockers-
Integr Blood Press Control. 2011; 4: 17–26.
View more products with following salts Irbesartan
